RHON-KLINIKUM AG RHK
XETR · Germany · Health Services
€14.40-0.30 (-2.04%)
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
30/09/2026 First half 2026:Revenue up 3.2%,EBITDA margin of 10.1%,and positive free cash flow of €11.1m 2026 targets revised upwards2027 financial targets confirmed in € millionsH1 2026H1 2025ChangeRevenue235.2227.9+3.2%Current EBITDA23.717.0+39.3%as % of revenue10.1%7.5%+261 bpsCurrent operating profit17.310.7+62.4%as % of revenue7.4%4.7%+269 bpsOperating profit17.19.4+81.4%Net financial result(3.6)0.15 Income tax expense(4.6)(1.2) Net income from continuing operations9.08.4+6.4%Net income from
The shareholders that have appointed the members of the nomination committee represented in aggregate 29.62 percent of all shares in the company as of 31 August 2026.
Martela Corporation, stock exchange release, 30 September 2026 at 10:00 a.m. (EEST) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, NEW ZEALAND, JAPAN, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Martela Corporation (hereinafter “Martela” or the “Company”) announced on 29 September 2026 that the Comp
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.